Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chromocell Therapeutics Corp ( (CHRO) ) just unveiled an update.
Channel Therapeutics Corporation, formerly Chromocell Therapeutics, has rebranded and reincorporated to emphasize its focus on non-opioid pain treatments using sodium channel modulation. The company is advancing its therapeutic programs, including eye pain and depot programs, with efficacy results anticipated soon. This strategic move is aimed at enhancing growth, valuation, and tax benefits.
Find detailed analytics on CHRO stock on TipRanks’ Stock Analysis page.